| Angioedemas, Hereditary
Firazyr vs Kalbitor
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Firazyr vs Kalbitor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKalbitor has a higher rate of injection site reactions vs Firazyr based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kalbitor but not Firazyr, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Firazyr
Kalbitor
At A Glance
SC injection
As needed (up to 3 doses/24 hours)
Bradykinin B2 receptor antagonist
SC injection
As needed
Plasma kallikrein inhibitor
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary 30 mg SC injection in the abdominal area; additional injections of 30 mg may be given at intervals of at least 6 hours if response is inadequate or symptoms recur; no more than 3 doses in any 24-hour period.
Angioedemas, Hereditary 30 mg (3 mL) subcutaneously in three 10 mg (1 mL) injections per attack; an additional 30 mg may be administered within 24 hours if the attack persists.
Contraindications
—
- Known clinical hypersensitivity to KALBITOR
Adverse Reactions
Most common (>1%) Injection site reactions, pyrexia, transaminase increased, dizziness, rash, nausea, headache
Postmarketing Urticaria
Most common (>=3%) Headache, nausea, diarrhea, pyrexia, injection site reactions, nasopharyngitis
Serious Hypersensitivity reactions including anaphylaxis
Postmarketing Similar adverse reactions as observed in clinical trials
Pharmacology
Bradykinin B2 receptor antagonist; icatibant competitively inhibits bradykinin from binding the B2 receptor, blocking the vasodilation, inflammation, and pain associated with bradykinin release in acute HAE attacks caused by C1-esterase-inhibitor deficiency or dysfunction.
Plasma kallikrein inhibitor; ecallantide is a potent, selective, reversible inhibitor of plasma kallikrein that blocks its binding site, reducing the conversion of HMW kininogen to bradykinin and thereby treating symptoms during acute episodic attacks of HAE.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Firazyr
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (8/12) · Qty limit (9/12)
Kalbitor
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Firazyr
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (2/8)
Kalbitor
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Firazyr
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Kalbitor
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FirazyrView full Firazyr profile
KalbitorView full Kalbitor profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.